Ginkgo Bioworks (DNA) Falls -10.2% Despite Strong Performance

Ginkgo Bioworks (DNA) shares fall 10.2% to $11.42, with a $1.30 decline.

Ginkgo Bioworks Holdings, Inc. (DNA) shares experienced a notable decline on Monday, falling 10.2% to close at $11.42, marking a $1.30 drop from the previous day's closing price of $12.72. This significant drop was preceded by a gap in trading, with the stock opening at $12.23 after closing at $12.72 the previous day [2].

The recent trading session saw a higher volume of shares traded, with 209,900 shares changing hands, compared to the stock's 50-day simple moving average of $8.34 and 200-day simple moving average of $9.10 [2]. Despite the decline, Ginkgo Bioworks continues to operate within the Zacks Medical - Biomedical and Genetics industry, alongside peers like Novavax (NVAX), which closed the last trading session 1.1% lower at $6.3 [1].

Ginkgo Bioworks' recent earnings report revealed a quarterly loss of $1.58 per share, falling short of the consensus estimate of $1.23 [2]. The company's revenue for the quarter amounted to $48.32 million, surpassing analyst estimates of $38.70 million [2]. The stock's Zacks Rank remains at #2 (Buy), indicating a potential for growth despite the recent setback [1].

Institutional investors have shown continued interest in Ginkgo Bioworks, with several large investors increasing their stakes in the company. Goldman Sachs Group Inc., for instance, increased its holdings by 25.4% during the first quarter, now owning 686,767 shares valued at $3,915,000 [2]. Despite the recent decline, the stock's fundamentals and the company's innovative platform for cell programming continue to attract investors.

References:
[1] https://www.nasdaq.com/articles/ginkgo-bioworks-dna-soars-189-further-upside-left-stock
[2] https://www.marketbeat.com/instant-alerts/ginkgo-bioworks-nysedna-shares-gap-down-time-to-sell-2025-07-07/